Assertio Holdings, Inc. Appoints Sravan Emany to Its Board of Directors
November 14 2023 - 8:00AM
Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ:
ASRT), a specialty pharmaceutical company that acquires,
commercializes and develops safe and effective therapies that make
a difference in the lives of patients, announced today that Sravan
Emany has been appointed to the Company’s Board of Directors. As
part of the appointment, Assertio has expanded its board to seven
seats. Mr. Emany currently serves as the Chief Financial Officer of
Ironwood Pharmaceuticals.
“Sravan is a highly regarded financial leader in
pharmaceuticals, and we are thrilled to have him join our Board of
Directors,” said Peter D. Staple, Chairman of Assertio. “Sravan’s
financial, capital markets and leadership perspectives will add
further depth to our Board.”
“I feel very privileged to join Assertio’s Board at such an
exciting time for the company. I see real opportunity to help the
Board and management achieve Assertio’s next chapter of growth and
transformation that will deliver meaningful shareholder value,”
said Mr. Emany.
Since December 2021, Mr. Emany has served as
Senior Vice President and Chief Financial Officer of Ironwood
Pharmaceuticals, a Nasdaq listed healthcare company. Prior to
joining Ironwood, Mr. Emany served as Corporate Vice President,
Commercial Excellence and Chief Strategy Officer of Integra
LifeSciences Holdings Corporation, a publicly traded global
healthcare company, from March 2020 until December 2021 and as Vice
President of Strategy, Treasury and Investor Relations from
February 2018 to March 2020. Prior to Integra, Mr. Emany served in
various mergers and acquisitions investment banking roles at Bank
of America and BofA Securities (formerly Bank of America Merrill
Lynch) from September 2008 to February 2018, culminating in his
service as managing director in the mergers and acquisitions group
where he led numerous mergers and acquisitions in the healthcare
sector. Mr. Emany also served in various other financial roles,
including with Goldman Sachs Group and Morgan Stanley.
Mr. Emany holds a B.A. in international
relations from The Johns Hopkins University and an M.A. in
international relations and international economics from The Johns
Hopkins School of Advanced International Studies.
About Assertio
Assertio is a specialty pharmaceutical company
that acquires, commercializes and develops safe and effective
therapies that make a difference in the lives of patients.
Utilizing a proprietary digital-focused commercialization approach
we can promote products across multiple therapeutic categories. We
strive to lead by example, embrace change, and make a positive
impact in our community while creating better experiences for our
employees, partners and shareholders. To learn more about Assertio
visit www.assertiotx.com.
Forward Looking Statements
Statements in this communication that are not
historical facts are forward-looking statements that reflect
Assertio's current expectations, assumptions and estimates of
future performance and economic conditions. These forward-looking
statements are made in reliance on the safe harbor provisions of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These
forward-looking statements relate to, among other things, future
events or the future performance or operations of Assertio,
including our ability to realize the benefits from our operating
model, successfully integrate new assets and explore new business
development initiatives. All statements other than historical facts
may be forward-looking statements and can be identified by words
such as "anticipate," "believe," "could," "design," "estimate,"
"expect," "forecast," "goal," "guidance," "imply," "intend," "may",
"objective," "opportunity," "outlook," "plan," "position,"
"potential," "predict," "project," "prospective," "pursue," "seek,"
"should," "strategy," "target," "would," "will," "aim" or other
similar expressions that convey the uncertainty of future events or
outcomes and are used to identify forward-looking statements. Such
forward-looking statements are not guarantees of future performance
and are subject to risks, uncertainties and other factors, some of
which are beyond the control of Assertio, including the risks
described in Assertio's Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q filed with the U.S. Securities and Exchange
Commission ("SEC") and in other filings Assertio makes with the SEC
from time to time.
Investors and potential investors are urged not
to place undue reliance on forward-looking statements in this
communication, which speak only as of this date. While Assertio may
elect to update these forward-looking statements at some point in
the future, it specifically disclaims any obligation to update or
revise any forward-looking-statements contained in this press
release whether as a result of new information or future events,
except as may be required by applicable law. Nothing contained
herein constitutes or will be deemed to constitute a forecast,
projection or estimate of the future financial performance or
expected results of Assertio.
Investor Contact:
Matt KrepsManaging DirectorDarrow AssociatesAustin, TX M:
214-597-8200mkreps@darrowir.com
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Apr 2024 to May 2024
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From May 2023 to May 2024